Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT01186458

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01186458. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma: Hoosier Oncology Group LYM08-134

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the effectiveness of fludarabine, Velcade, and rituximab treatment regimen in patients with relapsed or refractory follicular non-Hodgkin lymphoma.

Study identification

NCT ID: NCT01186458
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Hoosier Cancer Research Network; Other
Enrollment: 4 participants

Conditions and interventions

Conditions

Lymphoma, Non-Hodgkin

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2010 (Type not available)
Primary completion: Oct 2013 (Actual)
Completion: Oct 2013 (Actual)
Last update posted: Oct 24, 2016

2010 – 2013

United States locations

U.S. sites: 11
U.S. states: 5
U.S. cities: 9

Facility	City	State	ZIP	Site status
Cancer Care Center of Southern Indiana	Bloomington	Indiana	47403	—
Fort Wayne Oncology & Hematology, Inc	Fort Wayne	Indiana	46815	—
Indiana University Melvin and Bren Simon Cancer Center	Indianapolis	Indiana	46202	—
Community Regional Cancer Center	Indianapolis	Indiana	46256	—
Arnett Cancer Care	Lafayette	Indiana	47904	—
Virtua Health Cancer Program	Mount Holly	New Jersey	08060	—
South Jersey Health Care	Vineland	New Jersey	08360	—
University of Rochester Medical Center	Rochester	New York	14642	—
Case Comprehensive Cancer Center - University Hospitals Case Medical Center	Cleveland	Ohio	44106	—
Seidman Cancer Center	Cleveland	Ohio	44106	—
Reading Hospital Regional Cancer Center	West Reading	Pennsylvania	19611	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01186458, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 24, 2016 · Synced Nov 14, 2026